Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 23, 2026

Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know

View original at finance.yahoo.com
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know What Happened?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce is a Rule-of-40 company retiring 10% of its shares through a $25 billion buyback

    60% confidence
  • Salesforce is a Buy on valuation grounds

    60% confidence
  • The software sell-off has become indiscriminate; the market is pricing AI cannibalization as if it already happened while income statements may be indicating otherwise

    60% confidence
  • If the largest IT services firm in the world signals AI is eating its billable hours, investors will extend the same logic to software vendors whose products those hours configure

    60% confidence
  • AI agents will erode the subscription model that underpins traditional enterprise software economics

    60% confidence
  • Salesforce carries the largest AI revenue line in the enterprise software category

    60% confidence
  • The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks

    60% confidence
  • Salesforce is acquiring m3ter to monetize AI agent actions rather than per-seat subscriptions

    60% confidence
  • Until enterprise software companies prove AI revenue scales faster than it erodes the legacy subscription base, software stocks may remain in the penalty box even on days when chip stocks rally

    60% confidence
  • AI is compressing demand for traditional IT services

    60% confidence

Data points we hold from this source

Salesforce · stock price152 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know — Source | Via News | ViaNews Market